THAR - NASDAQ

Tharimmune, Inc.

Tharimmune, Inc.

THARยทNASDAQ

$3.38

+0.86%
HealthcareBiotechnology

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$133.41M
EPS-1.1200
P/E Ratio-3.14
Earnings Date06/03/2026
Tharimmune, Inc.

Tharimmune, Inc. Fair Value Envelope

THAR ยท NASDAQ

Our analysis suggests that THAR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.375, this represents a potential HIDDEN relative to our calculated worth for Tharimmune, Inc..

HIDDEN
Intrinsic Value
Current Price: $3.375

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$15.0M
+ Cash & Equivalents$17.0M
Firm Value$2.0M
- Debt$0
Equity Value$2.0M
/ Shares Outstanding35,044,810B
DCF Value$0
OVERVALUED BY 98%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$8.4M
-$4.4M
-$2.3M
-$1.2M
-$616.8K
-$321.1K
-$167.2K
-$87.0K
-$45.3K
-$23.6K
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$8.4M
-$4.4M
-$2.3M
-$1.2M
-$616.8K
-$321.1K
-$167.2K
-$87.0K
-$45.3K
-$23.6K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$7.8M
-$3.7M
-$1.8M
-$870.8K
-$419.8K
-$202.4K
-$97.5K
-$47.0K
-$22.7K
-$10.9K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your THAR research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.